Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD
2
Salvage Settings, Duration, and Next Steps in Very High-Risk Prostate Cancer
3
CHMP recommends EU approval of belzutifan plus lenvatinib for advanced ccRCC
4
Survey: Service members and veterans with NMIBC report barriers to treatment access
5